Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.
No entries.
Section 2 · machine-generated
Variations
Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.
Automated or data-driven variant
Raman feedback for l-tartrate crystallization
An immersion Raman probe collects spectra from an agitated L-tartrate crystallization slurry at fixed intervals. Software compares the spectra with reference spectra from the target crystalline form and dissolved components. A controller holds the jacket temperature when the target-form signal falls below a calibrated threshold and resumes cooling when the signal recovers. The controller flags the end of the batch when the target-form signal and a calibrated dissolved-compound signal both stabilize over a defined interval.
Robotic screening of solvent and humidity effects
A liquid-handling robot dispenses water and alcohol mixtures into separate wells containing weighed portions of the phosphate or L-tartrate salt. Replicate wells equilibrate under controlled humidity after solvent evaporation. An automated powder X-ray diffraction stage collects a diffraction pattern from each well. Software groups the patterns by peak position and flags groups with reproducible peak shifts or additional peaks for follow-up water-content and thermal measurements.
Section 3 · quoted from USPTO records
Other work
Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.
1.1the pharmaceutically acceptable salt is selected from the group consisting of a phosphate and an L-tartrate.
In another embodiment, the invention provides L-(+)-tartaric acid salt of isofagomine.
A · US 7,501,439 B2 · ¶ 16
In a further embodiment, the invention pertains to an L-tartrate salt of or complexes with a compound represented by Formulae I, II, III or IV.
B · US 8,846,912 B2 · ¶ 55
An empty cell means only that no passage was reproduced there.
Statements in these documents
Misfolded GCase is recognized by the ER quality control system and subsequently degraded instead of being processed and trafficking to the lysosome.
A · US 7,501,439 B2 · ¶ 2
Pharmacological chaperone methods for enhancing mutant enzyme activities in lysosomal storage disorders using enzyme inhibitors such as isofagomine are disclosed in commonly owned U.S.
A · US 7,501,439 B2 · ¶ 7
It would be advantageous to prepare pharmaceutically acceptable salts of these quinazoline compounds.
B · US 8,846,912 B2 · ¶ 7
As shown below in Example 53, tartrate salts or complexes of the quinazoline compounds have greater solubility and stability than the corresponding sodium, hydrochloride and citric acid salts.
B · US 8,846,912 B2 · ¶ 8
Cite aspatent.fyi, US 2026/0356837 A1, claim 1, first published 2026-11-20T08:11:50-05:00, https://patent.fyi/US20260356837/, SHA-256 800053f1b54c0565b123f9bb5c9969685048d2256cf40741c5d107d630486436